Publikationen 2023

Mackensen A, Mueller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, Volkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rosler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Kronke G, Schett G: (2023) Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2023;29(11):
Kretschmann S, Völkl S, Reimann H, Krönke G, Schett G, Achenbach S, Lutzny-Geier G, Müller F, Mougiakakos D, Dingfelder J, Flamann C, Hanssens L, Gary R, Mackensen A, Aigner M: (2023) Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus. Transplant Cell Ther. 2023;29(1): 27-33
Reimann H, Kremer AN, Blumenberg V, Schmidt KG, Aigner M, Jacobs B, Eisenhauer N, Kämpf A, Roesler W, Kharboutli S, Mougiakakos D, Lang V, Lischer C, Irrgang P, Leppkes M, Gonzalez JV, Krönke G, Kremer AE, Tenbusch M, Bruns H, Harrer T, Müller F, Schett G, Mackensen A, Subklewe M, Völkl S: (2023) Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy. Blood Adv. 2023;7(10): 2066-2069
Etra A, Capellini A, Alousi A, Al Malki MM, Choe H, DeFilipp Z, Hogan WJ, Kitko CL, Ayuk F, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Rösler W, Spyrou N, Young R, Chen YB, Ferrara JLM, Levine JE: (2023) Effective treatment of low-risk acute GVHD with itacitinib monotherapy. Blood. 2023;141(5): 481-489
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M: (2023) Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2023;9(4): 519-526
Reimann H, Moosmann C, Schober K, Lang VES, Verhagen J, Zeun J, Mackensen A, Kremer AN, Voelki S, Aigner M: (2023) Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains Immunobiology. 2023;228(5):
Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, Lueke F, Kutsch N, Mueller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter AM, Schulz-Eying C, Finlayson A, Flemmig C, Kuehlcke K, Preussner L, Rengstl B, Tuereci Ö, Sahin U: (2023) CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11): 2844-2853
Gsottberger F, Meier C, Ammon A, Parker S, Wendland K, George R, Petkovic S, Mellenthin L, Emmerich C, Lutzny-Geier G, Metzler M, Mackensen A, Chandramohan V, Mueller F: (2023) Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response Cell Death Dis. 2023;14(8):
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M: (2023) Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023;9(38):
Eckardt JN, Röllig C, Metzeler K, Kramer M, Stasik S, Georgi JA, Heisig P, Spiekermann K, Krug U, Braess J, Görlich D, Sauerland CM, Woermann B, Herold T, Berdel WE, Hiddemann W, Kroschinsky F, Schetelig J, Platzbecker U, Müller-Tidow C, Sauer T, Serve H, Baldus C, Schäfer-Eckart K, Kaufmann M, Krause S, Hänel M, Schliemann C, Hanoun M, Thiede C, Bornhäuser M, Wendt K, Middeke JM: (2023) Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. Haematologica. 2023;108(3): 690-704
Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, Kretschmann S, Reimann H, Harrer T, Bayerl N, Boeltz S, Wirsching A, Taubmann J, Rösler W, Spriewald B, Wacker J, Atzinger A, Uder M, Kuwert T, Mackensen A, Schett G: (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8): 1117-1120
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G: (2023) CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379): 815-818
Hippe K, Kreft A, Reu-Hofer S, Rosenwald A, Ferrazzi F, Daniel C, Amann K, Kraus S, Holler E, Kandulski A, Hirsch D, Buttner A, Rösler W, Hildner K, Winkler J, Büttner-Herold M: (2023) Round-Robin test for the histological diagnosis of acute colonic Graft-versus-Host disease validating established histological criteria and grading systems. Virchows Arch. 2023;483(1): 47-58
Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, Völkl S, Mackensen A, Schett G, Basu S: (2023) Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Mol Ther Methods Clin Dev. 2023;31():
Akahoshi Y, Spyrou N, Hogan WJ, Ayuk F, DeFilipp Z, Weber D, Choe HK, Hexner EO, Roesler W, Etra AM, Sandhu K, Yanik GA, Chanswangphuwana C, Kitko CL, Reshef R, Kraus S, Woelfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp SA, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine JE, Ferrara JLM, Chen YB: (2023) Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD Blood Adv. 2023;7(16): 4479-4491
Raach B, Bundgaard N, Haase MJ, Starruss J, Sotillo R, Stanifer ML, Graw F: (2023) Influence of cell type specific infectivity and tissue composition on SARS-CoV-2 infection dynamics within human airway epithelium PLoS Comput Biol. 2023;19(8):
Enssle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, Mikesch JH, Krause S, Sauer T, Hanoun M, Reinhardt HC, Kraus S, Kaufmann M, Haenel M, Fransecky L, Burchert A, Neubauer A, Crysandt M, Jost E, Niemann D, Schaefer-Eckart K, Held G, Kaiser U, Wass M, Schaich M, Mueller-Tidow C, Platzbecker U, Baldus CD, Bornhaeuser M, Roellig C, Serve H, Study Alliance Leukemia SAL , Steffen B: (2023) Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience Br J Cancer. 2023;129(7): 1126-1133
Malki MMA, London K, Baez J, Akahoshi Y, Hogan WJ, Etra A, Choe H, Hexner E, Langston A, Abhyankar S, Ponce DM, Defilipp Z, Kitko CL, Adekola K, Reshef R, Ayuk F, Capellini A, Chanswangphuwana C, Eder M, Eng G, Gandhi I, Grupp S, Gleich S, Holler E, Javorniczky NR, Kasikis S, Kowalyk S, Morales G, Oezbek U, Roesler W, Spyrou N, Yanik G, Young R, Chen YB, Nakamura R, Ferrara JLM, Levine JE: (2023) Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease Blood Adv. 2023;7(17): 5189-5198
Kayser S, Martinez-Cuadron D, Rodriguez-Veiga R, Haenel M, Tormo M, Schaefer-Eckart K, Botella C, Stoelzel F, del Castillo TB, Keller U, Rodriguez-Medina C, Held G, Amigo ML, Schliemann C, Colorado M, Kaufmann M, Garcia MB, Krause SW, Goerner M, Jost E, Steffen B, Zukunft S, Platzbecker U, Ho AD, Baldus CD, Serve H, Mueller-Tidow C, Thiede C, Bornhaeuser M, Montesinos P, Roellig C, Schlenk RF: (2023) Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia Haematologica. 2023;108(8): 2059-2066
Burmeister T, Groeger D, Goekbuget N, Spriewald B, Starck M, Elmaagacli A, Hoelzer D, Keller U, Schwartz S: (2023) Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment Sci Rep. 2023;13(1):
Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C: (2023) Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification. Leukemia. 2023;37(11): 2282-2285
Eckardt JN, Stasik S, Roellig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Bruemmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schaefer-Eckart K, Schliemann C, Krause SW, Herbst R, Haenel M, Hanoun M, Kaiser U, Kaufmann M, Racil Z, Mayer J, Oelschlaegel U, Berdel WE, Ehninger G, Serve H, Mueller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhaeuser M, Middeke JM, Thiede C: (2023) Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Leukemia. 2023;():
Hoffmann J, Eminovic S, Wilhelm C, Krause SW, Neubauer A, Thrun MC, Ultsch A, Brendel C: (2023) Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia Curr Oncol. 2023;30(2): 1903-1915
Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, Roesler W, Spriewald B, Tischer J, Moi S, Balzer H, Schaffer S, Bausenwein J, Wagner A, Schmidt F, Brestrich J, Ullrich B, Maas S, Herold S, Strobel J, Zimmermann R, Weisbach V, Hansmann L, Lammoglia-Cobo F, Remberger M, Stelljes M, Ayuk F, Zeiser R, Mackensen A: (2023) Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Front Immunol. 2023;14():
Blumenberg V, Galina B, Baumann S, Jitschin R, Iacoboni G, Hoster E, Gallur L, Iraola-Truchuelo J, Winkelmann M, Hellwig K, Schmidt C, Frölich L, Tast B, Hildebrand F, Rejeski K, Dekorsy FJ, Schmidkonz C, Bäuerle T, Kunz WG, Mougiakakos D, Müller F, von Bergwelt-Baildon M, Barba P, Bücklein VL, Mackensen A, Völkl S, Subklewe M: (2023) Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL. Blood Adv. 2023;7(22): 6844-6849
Küchenhoff L, Lukas P, Metz-Zumaran C, Rothhaar P, Ruggieri A, Lohmann V, Höfer T, Stanifer ML, Boulant S, Talemi SR, Graw F: (2023) Extended methods for spatial cell classification with DBSCAN-CellX. Sci Rep. 2023;13(1):
Alamoudi E, Schälte Y, Müller R, Starruß J, Bundgaard N, Graw F, Brusch L, Hasenauer J: (2023) FitMultiCell: simulating and parameterizing computational models of multi-scale and multi-cellular processes. Bioinformatics. 2023;39(11):
Naschberger E, Fuchs M, Dickel N, Kunz M, Popp B, Anchang CG, Demmler R, Lyu Y, Uebe S, Ekici AB, Geppert CI, Hartmann A, Flierl C, Petter K, Gass T, Völkl S, Scharl M, Ramming A, Günther C, Merkel S, Schellerer VS, Stürzl M: (2023) Tumor microenvironment-dependent epigenetic imprinting in the vasculature predicts colon cancer outcome. Cancer Commun (Lond). 2023;43(11): 1280-1285
Lischer C, Bruns H: (2023) Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment. Cell Rep Med. 2023;4(10):
Baur R, Karl F, Böttcher-Loschinski R, Stoll A, Völkl S, Gießl A, Flamann C, Bruns H, Schlötzer-Schrehardt U, Böttcher M, Schewe DM, Fischer T, Jitschin R, Mackensen A, Mougiakakos D: (2023) Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy. J Immunother Cancer. 2023;11(3):
Schett G, Mackensen A, Mougiakakos D: (2023) CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416): 2034-2044
Ruhnke L, Röllig C, Herold S, Sauer T, Brandts CH, Steffen B, Schäfer-Eckart K, Krause SW, Hänel M, Reichle A, Scholl S, Neubauer A, Mikesch JH, Schetelig J, Stölzel F, Kramer M, Haake A, Frimmel J, Krämer A, Schlenk R, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Aust D, Bornhäuser M, Ehninger G, Thiede C: (2023) Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial. Haematologica. 2023;108(9): 2520-2525
Spyrou N, Akahoshi Y, Ayuk F, Holler E, Choe H, Etra A, Hogan WJ, Rösler W, Hexner E, DeFilipp Z, Reshef R, Chanswangphuwana C, Qayed M, Kraus S, Eder M, Javorniczky NR, Grupp SA, Kitko CL, Merli P, Aguayo-Hiraldo P, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Khan A, Kowalyk S, Morales G, Young R, Nakamura R, Chen YB, Levine JE, Ferrara JLM: (2023) The utility of biomarkers in acute GVHD prognostication. Blood Adv. 2023;7(17): 5152-5155
Derigs P, Bethge WA, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P, German Lymphoma Alliance and the German Registry for Stem Cell Transplantation: (2023) Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis. Transplant Cell Ther. 2023;29(12): 750-756
Tögel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K, Moskalev EA, Stöhr R, Agaimy A, Reis A, Wullich B, Mackensen A, Pavel M, Beckmann MW, Hartmann A, Fietkau R, Meidenbauer N, Haller F, Spoerl S: (2023) Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center. Cancers (Basel). 2023;15(24):
Weiss L, Dorman K, Boukovala M, Schwinghammer F, Jordan P, Fey T, Hasselmann K, Subklewe M, Bücklein V, Bargou R, Goebeler M, Sayehli C, Spoerl S, Lüke F, Heudobler D, Claus R, von Luettichau I, Lorenzen S, Lange S, Westphalen CB, von Bergwelt-Baildon M, Heinemann V, Gießen-Jung C: (2023) Early clinical trial unit tumor board: a real-world experience in a national cancer network. J Cancer Res Clin Oncol. 2023;149(14): 13383-13390
Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Schroers R, Wolff D, Thomas S, Kröger N, Bethge WA, German Lymphoma Alliance (GLA) , German Stem Cell Transplantation Registry (DRST): (2023) Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience. Bone Marrow Transplant. 2023;58(2): 229-232
Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, Einsele H, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C, Study Alliance Leukemia (SAL): (2023) Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry. J Cancer Res Clin Oncol. 2023;149(8): 4611-4621
Schubert ML, Bethge WA, Ayuk FA, von Bonin M, Vucinic V, Wagner-Drouet EM, Subklewe M, Baldus CD, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp MS, Wulf G, Kröger N, Dreger P: (2023) Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study. Blood Adv. 2023;7(20): 6191-6195
Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, Koenecke C, Bakhtiar S, Künkele A, Meisel R, Müller F, Müller I, Penack O, Rettinger E, Sauer MG, Schlegel PG, Soerensen J, von Stackelberg A, Strahm B, Hauer J, Feuchtinger T, Jarisch A: (2023) CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023;7(11): 2436-2448
Häselbarth L, Gamali S, Saul D, Krumbholz M, Böttcher-Loschinski R, Böttcher M, Zou D, Metzler M, Karow A, Mougiakakos D: (2023) Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment. BMC Cancer. 2023;23(1):
Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD: (2023) Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. Hemasphere. 2023;7(8):
Eckardt JN, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi JA, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, Krug U, Braess J, Görlich D, Sauerland C, Woermann B, Herold T, Hiddemann W, Müller-Tidow C, Serve H, Baldus CD, Schäfer-Eckart K, Kaufmann M, Krause SW, Hänel M, Berdel WE, Schliemann C, Mayer J, Hanoun M, Schetelig J, Wendt K, Bornhäuser M, Thiede C, Middeke JM: (2023) Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):
Heidenreich F, Falk B, Baldauf H, Massalski C, Schaefer G, Ruecker-Braun E, Altmann H, Sauter J, V. Solloch UV, Lange V, Stoelzel F, Roellig C, Middeke JM, von Bonin M, Thiede C, Schaefer-Eckart K, Mueller-Tidow C, Krause SW, Kraus S, Kaufmann M, Haenel M, Serve H, Neubauer A, Bornhaeuser M, Schmidt AH, Schetelig J: (2023) Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia Blood Adv. 2023;7(13): 2994-3004
Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, Röllig C, Middeke JM, Oelschlägel U, Krug U, Sauer T, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Hänel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Kroschinsky F, Thiede C, Study Alliance Leukemia (SAL): (2023) UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome. Blood Cancer J. 2023;13(1):
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki M, Ayuk FA, Bader P, Baez J, Capellini A, Choe H, Defilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp S, Hexner E, Hoepting M, Hogan WJ, Kasikis S, Katsivelos N, Kitko CL, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter-Finkelstein T, Vasova I, Woelfl M, Wudhikarn K, Young R, Holler E, Chen YB, Nakamura R, Levine J, Ferrara JLM: (2023) A Day 14 Endpoint for Acute Gvhd Clinical Trials Blood. 2023;142 Suppl 1():
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk FA, Bunworasate U, Choe H, Eder M, Etra A, Grupp S, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Merli P, Qayed M, Reshef R, Schechter-Finkelstein T, Ullrich E, Vasova I, Woelfl M, Zeiser R, Baez J, Beheshti R, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen YB, Ferrara JLM, Levine J, Nakamura R: (2023) Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study Blood. 2023;142 Suppl 1():
Defilipp Z, Kim HT, Spyrou N, Kowalyk S, Eng G, Beheshti R, Baez J, Ayuk FA, Choe H, Etra A, Grupp S, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Ferrara JLM, Nakamura R, Levine J, Chen YB: (2023) The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd Blood. 2023;142 Suppl 1():
Bill M, Eckardt JN, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Bruemmendorf TH, Krug U, Woermann B, Hiddemann W, Goerlich D, Sauerland MC, Steffen B, Einsele H, Neubauer A, Burchert A, Schaefer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Mueller-Tidow C, Bornhaeuser M, Herold T, Thiede C, Roellig C: (2023) Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1-Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients Blood. 2023;142 Suppl 1():

Schriftgröße anpassen

Publikationen 2023

Publikationen 2023

Notfall

Notfallinformationen UKER

Patienten & Besucher

Ärzte & Zuweiser

Forschung

Lehre